How much dividend does ImmuPharma pay?
Over the past 12 months, ImmuPharma paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, ImmuPharma is expected to pay a dividend of 0 GBP.
ImmuPharma Dividend 2024
ImmuPharma Dividend
0 GBP
ImmuPharma Dividend yield
Ticker
IMM.L
ISIN
GB0033711010
WKN
A0BMC4
How much dividend does ImmuPharma 2024 pay?
According to the latest status from October 2024, ImmuPharma paid a total of 0 GBP per share in dividends within the last 12 months. With the current ImmuPharma price of 0.02 GBP, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| = |
Historical ImmuPharma Dividends
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|
Is the ImmuPharma Dividend Safe?
ImmuPharma has been increasing the dividend for 0 years.
Over the past 10 years, ImmuPharma has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Dividend Details
Understanding ImmuPharma's Dividend Distributions
ImmuPharma’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining ImmuPharma's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
ImmuPharma's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in ImmuPharma’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
ImmuPharma Aktienanalyse
What does ImmuPharma do?
ImmuPharma PLC is a biopharmaceutical company specializing in the development of drugs for the treatment of autoimmune diseases and cancer. The company was founded in 1999 and is headquartered in London, England. ImmuPharma's history began with the discovery of a new peptide extracted from the trail of a snail. This substance has potent immunomodulatory potential and can inhibit the growth of certain tumor cells. ImmuPharma recognized the potential of this discovery and began developing a new drug based on this peptide. ImmuPharma's business model is to develop innovative drugs and license or sell them to large pharmaceutical companies. The company works closely with leading scientists and experts in drug development to ensure the efficacy and safety of its products. ImmuPharma has focused on two main areas: autoimmune diseases and cancer. Autoimmune diseases are conditions in which the immune system malfunctions and attacks the body. The autoimmune diseases that ImmuPharma targets include lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and myasthenia gravis. ImmuPharma has also developed a drug called Lupuzor for the treatment of systemic lupus erythematosus (SLE). SLE is a severe autoimmune disease that causes inflammation and pain in various parts of the body. Lupuzor was developed as a first-in-class drug that regulates the immune system and reduces inflammation without compromising the body's normal defense function. In the field of cancer, ImmuPharma has also developed promising products that aim to inhibit tumor progression. The company has identified and tested a range of peptide- and protein-based drug candidates, including IPP-204106, which is used for the treatment of advanced prostate cancer. Last year, ImmuPharma also developed a new drug called Ureka for the treatment of urinary tract infections. Ureka is a bacterial toxin that specifically targets E. coli bacteria, which are the most common cause of urinary tract infections. In recent years, ImmuPharma has entered into several important partnerships to advance the development of its drugs. One partnership is with the Chinese company Avion Pharmaceuticals, which holds the marketing rights for Lupuzor in North America, Australia, and New Zealand. Another partnership is with the US company Orphan Reach, which supports the development and marketing of Ureka. Overall, ImmuPharma represents innovation and progress in drug development. The company is dedicated to a crucial purpose, seeking cures for those suffering from autoimmune diseases and cancer. Through a combination of scientific excellence and strategic partnerships, ImmuPharma has the potential to achieve significant therapeutic advancements and improve the lives of countless patients. ImmuPharma is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Frequently Asked Questions about ImmuPharma stock
What is the dividend yield of ImmuPharma?
The current dividend yield of ImmuPharma is .
When does ImmuPharma pay dividends?
ImmuPharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of ImmuPharma?
ImmuPharma paid dividends every year for the past 0 years.
What is the dividend of ImmuPharma?
For the upcoming 12 months, dividends amounting to 0 GBP are expected. This corresponds to a dividend yield of 0 %.
In which sector is ImmuPharma located?
ImmuPharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von ImmuPharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of ImmuPharma from 10/2/2024 amounting to 0 GBP, you needed to have the stock in your portfolio before the ex-date on 10/2/2024.
When did ImmuPharma pay the last dividend?
The last dividend was paid out on 10/2/2024.
What was the dividend of ImmuPharma in the year 2023?
In the year 2023, ImmuPharma distributed 0 GBP as dividends.
In which currency does ImmuPharma pay out the dividend?
The dividends of ImmuPharma are distributed in GBP.
Andere Kennzahlen von ImmuPharma
Our stock analysis for ImmuPharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of ImmuPharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
